DMF in CTCL: where do we go from here?

In this issue of Blood, Nicolay et al demonstrate that targeting the NF-kappa B pathway with oral dimethyl fumarate (DMF) may be effective in certain patients with mycosis fungoides and Sezary syndrome (MF/SS).(1) Building on their preclinical data demonstrating that DMF restores apoptosis sensitivity among malignant cells,2 the authors demonstrate the activity of single-agent DMF in a heterogeneous population of patients with relapsed or refractory stage IB-IV MF/SS in this phase 2 multicenter clinical trial.

Automated summary

This study demonstrates the potential effectiveness of targeting the NF-kappa B pathway with oral dimethyl fumarate (DMF) in certain patients with mycosis fungoides and Sezary syndrome (MF/SS).